Sort
82,697 grants matching “vaccine development”
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy
$884,291Marie Bleakley · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA
Fusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primates
$884,211Andrew Barrett Ward · Scripps Research Institute, The · R01 · FY2021 · AI
Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection
$884,064Theodore Pierson · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Thermostable measles fusion glycoprotein as a new vaccine strategy
$883,864Matteo Porotto · Columbia University Health Sciences · R56 · FY2024 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS
$883,666Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2020 · AI
B-1 B cell responses to oligomannosyl antigens of HIV-1
$883,603Denong Wang · Sri International · R56 · FY2015 · AI
Human Skin Disease Resource-based Center
$883,401Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2017 · AR
Human Skin Disease Resource-based Center
$883,401Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2019 · AR
Human Skin Disease Resource-based Center
$883,246Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2021 · AR
Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants
$883,231Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2019 · AI
HIV-1 Envelope Glycoproteins
$883,218Joseph G Sodroski · Dana-Farber Cancer Inst · R37 · FY2012 · AI
Antibody effector function in protection against HIV-1
$883,126Dennis R. Burton · Scripps Research Institute, The · R37 · FY2013 · AI
Maximizing germinal centers and somatic hypermutation to HIV Env immunogens
$883,119Shane P Crotty · La Jolla Institute For Immunology · R37 · FY2022 · AI
Novel Hepatitis B Vaccine and Immunotherapy
$883,119Mansun Law · Scripps Research Institute, The · R56 · FY2024 · AI
New Approaches To Active Immunoprophylaxis
$883,114Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
HIV AND SUBSTANCE ABUSE LABORATORY CORE
$883,112Eddy Rios-Olivares · Universidad Central Del Caribe · G12 · FY2011 · RR
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
$883,101Sudhir Pai Kasturi · Emory University · R01 · FY2022 · AI
NHP MHC ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT for transplantation studies
$883,078Daniel Geraghty · Fred Hutchinson Cancer Research Center · N01 · FY2020 · AI
Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine
$882,985John Adams · University Of South Florida · U01 · FY2025 · AI
Host Immunity Against Bacteria
$882,903Sandip Datta · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
$882,847Sudhir Pai Kasturi · Emory University · R01 · FY2023 · AI
Human Skin Disease Resource-based Center
$882,841Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2025 · AR
Human Skin Disease Resource-based Center
$882,841Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2022 · AR
Human Skin Disease Resource-based Center
$882,841Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2024 · AR
Human Skin Disease Resource-based Center
$882,841Rachael Ann Clark · Brigham And Women'S Hospital · P30 · FY2023 · AR